DE3853028T2 - Antikörper-Enzym-Konjugate in Verbindung mit Wirkstoff-Vorläufern zur Freisetzung von cytotoxischen Mitteln in den Tumorzellen. - Google Patents

Antikörper-Enzym-Konjugate in Verbindung mit Wirkstoff-Vorläufern zur Freisetzung von cytotoxischen Mitteln in den Tumorzellen.

Info

Publication number
DE3853028T2
DE3853028T2 DE3853028T DE3853028T DE3853028T2 DE 3853028 T2 DE3853028 T2 DE 3853028T2 DE 3853028 T DE3853028 T DE 3853028T DE 3853028 T DE3853028 T DE 3853028T DE 3853028 T2 DE3853028 T2 DE 3853028T2
Authority
DE
Germany
Prior art keywords
tumor cells
antibody
conjunction
enzyme
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3853028T
Other languages
English (en)
Other versions
DE3853028D1 (de
Inventor
Peter D Senter
Mark G Saulnier
Joseph P Brown
David E Kerr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/211,301 external-priority patent/US4975278A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE3853028D1 publication Critical patent/DE3853028D1/de
Application granted granted Critical
Publication of DE3853028T2 publication Critical patent/DE3853028T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE3853028T 1987-08-04 1988-08-03 Antikörper-Enzym-Konjugate in Verbindung mit Wirkstoff-Vorläufern zur Freisetzung von cytotoxischen Mitteln in den Tumorzellen. Expired - Lifetime DE3853028T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8138287A 1987-08-04 1987-08-04
US16106888A 1988-02-26 1988-02-26
US07/211,301 US4975278A (en) 1988-02-26 1988-06-29 Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Publications (2)

Publication Number Publication Date
DE3853028D1 DE3853028D1 (de) 1995-03-23
DE3853028T2 true DE3853028T2 (de) 1995-12-14

Family

ID=27373967

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3856112T Expired - Lifetime DE3856112T2 (de) 1987-08-04 1988-08-03 Anthracyclin Prodrugs
DE3853028T Expired - Lifetime DE3853028T2 (de) 1987-08-04 1988-08-03 Antikörper-Enzym-Konjugate in Verbindung mit Wirkstoff-Vorläufern zur Freisetzung von cytotoxischen Mitteln in den Tumorzellen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3856112T Expired - Lifetime DE3856112T2 (de) 1987-08-04 1988-08-03 Anthracyclin Prodrugs

Country Status (19)

Country Link
EP (2) EP0540859B1 (de)
JP (2) JP2738414B2 (de)
KR (1) KR930006757B1 (de)
AT (2) ATE162196T1 (de)
AU (1) AU614532B2 (de)
CA (1) CA1336887C (de)
DE (2) DE3856112T2 (de)
DK (1) DK175406B1 (de)
EG (1) EG18751A (de)
ES (1) ES2068191T3 (de)
FI (1) FI98197C (de)
GR (1) GR3015065T3 (de)
HU (1) HU207230B (de)
IE (2) IE68309B1 (de)
IL (1) IL87319A (de)
NO (1) NO178138C (de)
NZ (1) NZ225599A (de)
PT (2) PT88187B (de)
YU (1) YU150888A (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
KR0185967B1 (ko) * 1989-01-23 1999-05-01 에프. 쥐. 엠. 헤르만스; 에이. 쥐. 제이. 베르미렌 치료용 약물의 부위 특이적 생체내 활성작용
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
DE3935016A1 (de) * 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5270196A (en) * 1989-10-20 1993-12-14 Bristol-Myers Squibb Company Arylsulfatase from streptomyces
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
EP0505357B1 (de) * 1989-12-11 1999-03-10 Immunomedics, Inc. Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
GB9001641D0 (en) * 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
KR920007937B1 (ko) * 1990-01-30 1992-09-19 현대자동차 주식회사 밸브시트용 철(Fe)계 소결합금
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten
KR100208957B1 (ko) * 1990-04-25 1999-07-15 로렌스 티. 마이젠헬더 신규한 cc-1065 유사체
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
EP0647450A1 (de) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Verbesserte Prodrogen für Enzym-vermittelten-Aktivierungen
US5459248A (en) * 1993-11-04 1995-10-17 Bristol-Myers Squibb Company Process of preparing etoposide phosphate and etoposide
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5516679A (en) * 1994-12-23 1996-05-14 Bristol-Myers Squibb Company Penicillin V amidohydrolase gene from Fusarium oxysporum
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
JPH1160499A (ja) * 1997-08-22 1999-03-02 Hiroshi Maeda 抗腫瘍剤
US6159706A (en) * 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
WO2001093826A1 (fr) * 2000-06-06 2001-12-13 Sumitomo Pharmaceuticals Company, Limited Preparations polymere synthetiques biocompatibles
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
DE60237915D1 (en) * 2001-12-03 2010-11-18 Universitaetsklinikum Charite Podophyllotoxine als antiproliferative mittel
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1735350B1 (de) * 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
WO2008024103A1 (en) * 2006-08-21 2008-02-28 Essential Skincare, Llc Compositions to reduce or prevent skin cancer
CN112272673A (zh) * 2018-01-04 2021-01-26 上海晟顺生物科技有限公司 单域抗体-胞嘧啶脱氨酶融合蛋白

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1578734A (de) * 1967-11-28 1969-08-22
FR2122695A5 (en) * 1971-01-20 1972-09-01 Rhone Poulenc Sa Antibiotics duborimycin and 27706rp - by reduction of daunorubicin and adriamycin
FR2397425A1 (fr) 1977-07-11 1979-02-09 Rhone Poulenc Ind Nouveaux derives de la daunorubicine, leur preparation et les compositions qui les contiennent
CA1168150A (en) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
EP0142905A2 (de) 1983-03-30 1985-05-29 Bio-Response Inc. Therapeutisches Mittel für die Behandlung von Krankheiten wie Krebs
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
EP0202245A1 (de) * 1984-11-23 1986-11-26 Sri International C-glykosid-adriamycin-analoga
US4906562A (en) 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
DE3500023A1 (de) * 1985-01-02 1986-07-10 Farmitalia Carlo Erba S.p.A., Mailand/Milano 4'-desoxyanthracyclinester
FR2584294B1 (fr) 1985-07-08 1992-02-21 Berdal Pascal Compositions pharmaceutiques a visee cytotrophique
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems

Also Published As

Publication number Publication date
GR3015065T3 (en) 1995-05-31
ATE162196T1 (de) 1998-01-15
NO178138C (no) 1996-01-31
JPH02223532A (ja) 1990-09-05
KR930006757B1 (ko) 1993-07-23
NO883414D0 (no) 1988-08-02
EP0302473B1 (de) 1995-02-15
JPH10130295A (ja) 1998-05-19
HU207230B (en) 1993-03-29
ES2068191T3 (es) 1995-04-16
PT101702B (pt) 1999-11-30
JP3127136B2 (ja) 2001-01-22
IL87319A0 (en) 1990-02-09
DE3853028D1 (de) 1995-03-23
ATE118354T1 (de) 1995-03-15
NZ225599A (en) 1991-09-25
EP0302473A3 (en) 1990-01-17
PT88187A (pt) 1989-06-30
NO178138B (no) 1995-10-23
NO883414L (no) 1989-02-06
EP0540859A1 (de) 1993-05-12
IE882379L (en) 1989-02-04
IL87319A (en) 1995-08-31
FI98197B (fi) 1997-01-31
AU2020188A (en) 1989-05-25
EP0302473A2 (de) 1989-02-08
DK434188D0 (da) 1988-08-03
JP2738414B2 (ja) 1998-04-08
DK434188A (da) 1989-02-05
EG18751A (en) 1993-12-30
EP0540859B1 (de) 1998-01-14
FI98197C (fi) 1997-05-12
DE3856112T2 (de) 1998-08-27
DE3856112D1 (de) 1998-02-19
FI883597A (fi) 1989-02-05
KR890003408A (ko) 1989-04-14
DK175406B1 (da) 2004-09-27
PT88187B (pt) 1995-12-29
YU150888A (en) 1990-06-30
FI883597A0 (fi) 1988-08-01
IE950981L (en) 1989-02-04
IE68309B1 (en) 1996-06-12
PT101702A (pt) 1996-01-31
CA1336887C (en) 1995-09-05
HUT47437A (en) 1989-03-28
AU614532B2 (en) 1991-09-05

Similar Documents

Publication Publication Date Title
DE3853028D1 (de) Antikörper-Enzym-Konjugate in Verbindung mit Wirkstoff-Vorläufern zur Freisetzung von cytotoxischen Mitteln in den Tumorzellen.
PL307226A1 (en) Derivatives of nitrous yperite and amino acid and their application as ancillary drug in treating neoplasms
DE3853792T2 (de) Amin-Derivate von Anthracyclin-Antibiotika.
IL88428A0 (en) Anti-tumor drug-monoclonal antibody conjugates
DE69013740T2 (de) Immunokonjugate und Prodrogen und ihre gemeinschaftliche Anwendung für die Verabreichung von Arzneimitteln.
GB1446536A (en) Pharmaceutically active compositions
ES2064613T3 (es) Produccion de agentes citotoxicos.
EP0745390A3 (de) Polymerische Prodrogen für Beta-Lactamase und ihre Verwendung
FI884240A (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
MY103598A (en) Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells.
ES2113904T3 (es) Profarmacos de antraciclinas.

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition